

Jeromie M Ballreich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8408916/publications.pdf>

Version: 2024-02-01

29
papers

484
citations

759055

12
h-index

713332

21
g-index

29
all docs

29
docs citations

29
times ranked

611
citing authors

#	ARTICLE	IF	CITATIONS
1	Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. JAMA Network Open, 2018, 1, e183044.	2.8	98
2	Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. Journal of Medical Economics, 2021, 24, 1060-1069.	1.0	51
3	Attributes common to programs that successfully treat high-need, high-cost individuals. American Journal of Managed Care, 2015, 21, e597-600.	0.8	43
4	Equitable Access to Care – How the United States Ranks Internationally. New England Journal of Medicine, 2014, 371, 1567-1570.	13.9	40
5	Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. JAMA Network Open, 2018, 1, e180235.	2.8	37
6	Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. International Forum of Allergy and Rhinology, 2021, 11, 1626-1636.	1.5	27
7	Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019. JAMA Network Open, 2021, 4, e2034890.	2.8	27
8	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. JAMA Network Open, 2020, 3, e2023677.	2.8	24
9	Does Fracture Care Make Money for the Hospital? An Analysis of Hospital Revenues and Costs for Treatment of Common Fractures. Journal of Orthopaedic Trauma, 2015, 29, e219-e224.	0.7	23
10	Bridging the Silos of Service Delivery for High-Need, High-Cost Individuals. Population Health Management, 2016, 19, 421-428.	0.8	23
11	Factors associated with high short-acting Î2-agonist use in urban children with asthma. Annals of Allergy, Asthma and Immunology, 2015, 114, 385-392.	0.5	21
12	Cost-effectiveness of School Hearing Screening Programs: A Scoping Review. Otolaryngology - Head and Neck Surgery, 2020, 162, 826-838.	1.1	15
13	Reducing Branded Prescription Drug Prices: A Review of Policy Options. Pharmacotherapy, 2017, 37, 1469-1478.	1.2	10
14	Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. Addiction, 2022, 117, 969-976.	1.7	7
15	Medicare Spending on Drugs With Accelerated Approval. Annals of Internal Medicine, 2022, 175, 938-944.	2.0	7
16	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. Value in Health, 2022, 25, 796-802.	0.1	6
17	Branded prescription drug spending: a framework to evaluate policy options. Journal of Pharmaceutical Policy and Practice, 2017, 10, 31.	1.1	5
18	Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. JAMA Oncology, 2021, 7, 1720-1721.	3.4	4

#	ARTICLE	IF	CITATIONS
19	Affording Genetic Therapies in the Medicaid Program. JAMA Pediatrics, 2020, 174, 523.	3.3	3
20	Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry. Applied Health Economics and Health Policy, 2018, 16, 753-763.	1.0	2
21	Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. PLoS ONE, 2019, 14, e0225109.	1.1	2
22	The Association Between Drug Approvals and Burden of Disease From 1990 to 2017. Journal of General Internal Medicine, 2021, 36, 3615-3617.	1.3	2
23	Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 39-47.	0.5	2
24	Estimating & Comparing Greenhouse Gas Emissions for Existing Intramuscular COVID-19 Vaccines and a Novel Thermostable Oral Vaccine. The Journal of Climate Change and Health, 2022, , 100127.	1.4	2
25	Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019. JAMA Health Forum, 2022, 3, e220888.	1.0	2
26	Biosimilar uptake of filgrastim and impact on spending in Medicare Part D from 2015 to 2019.. Journal of Clinical Oncology, 2021, 39, 67-67.	0.8	1
27	Provider and Patient Characteristics of Medicare Beneficiaries Who Are High-Risk for COVID-19 Mortality. Journal of General Internal Medicine, 2021, 36, 2189-2190.	1.3	0
28	Consider expenditure controlsâ€™ impacts on equity. EClinicalMedicine, 2021, 36, 100913.	3.2	0
29	Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. JAMA Network Open, 2022, 5, e221117.	2.8	0